Rallybio financials
$17.22+1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $858.0K | $636.0K | $0.00 | $0.00 | — |
| Gross profit | $858.0K | $636.0K | $0.00 | $0.00 | — |
| Gross margin | 100.0% | 100.0% | — | — | — |
| Operating income | -$33.1M | -$60.5M | -$78.9M | -$67.9M | -$45.6M |
| Net income | -$9.0M | -$57.8M | -$74.6M | -$66.7M | -$47.0M |
| Net margin | −1046.4% | −9084.1% | — | — | — |
| Diluted EPS | $-1.59 | $-10.61 | $-14.72 | $-16.72 | $-14.72 |
| EBITDA | -$33.0M | -$60.4M | -$78.8M | -$67.7M | -$45.5M |
| Operating cash flow | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.5M |
| Free cash flow | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.9M |
| Diluted shares | 5.6M | 5.4M | 5.1M | 4.0M | 3.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $31.4M | $13.9M | $24.5M | $57.0M | $175.3M |
| Short-term investments | $23.4M | $51.6M | $85.4M | $112.0M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $62.3M | $68.1M | $115.6M | $180.4M | $182.2M |
| Total liabilities | $4.3M | $6.5M | $9.4M | $11.1M | $6.6M |
| Shareholders' equity | $58.0M | $61.7M | $106.2M | $169.3M | $175.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology